Oral treatment for Cdiff

In this nonrandomized single center trial of patients with mild Cdiff, those treated with IV metronidazole higher significantly higher mortality than those treated with oral metronidazole or oral vancomycin, even after adjusting for potential confounders. Oral treatment for mild Cdiff should be given whenever feasible, which is consistent with current guidelines (abstract)

Danielle Scheurer

Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.

Leave a Comment